在2型糖尿病治疗中甘精胰岛素联合瑞格列奈的应用安全性分析

目的 评价对2型糖尿病患者应用甘精胰岛素联合瑞格列奈的临床价值以及安全性分析.方法 选取时间为2017年9月—2019年4月,对该医院收治的138例2型糖尿病患者开展研究,采用数字随机表法将其平均分成2组(实验组与参照组),每组69例.其中参照组运用诺和灵30R治疗,实验组运用甘精胰岛素联合瑞格列奈治疗.对其治疗前后血...

Safety Analysis of Insulin Glargine Combined with Repaglinide in the Treatment of Type 2 Diabetes

Objective To evaluate the clinical value and safety analysis of insulin glargine combined with repaglinide in patients with type 2 diabetes.Methods The case selection period was from September 2017 to April 2019.A project study was carried out on 138 patients with type 2 diabetes admitted to the hospital,and they were equally divided into two groups(experimental group and reference group)by using the digital random table method.69 cases were in the each group.The reference group was treated with Novolin 30R,and the experimental group was treated with insulin glargine combined with repaglinide.Statistics on blood glucose levels before and after treatment,treatment effects,and adverse reactions were compared.Results After treatment,the fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin and other blood glucose indicators of the experimental group were lower than the reference group,and the comparison between the groups,the difference was statistically significant(P<0.05);the total adverse reactions in the experimental group of 5.80%(4/69)was lower than the total incidence of adverse reactions in the reference group 17.39%(12/69),and the total effective rate of treatment in the experimental group was 95.65%(66/69)higher than the total effective rate of treatment in the reference group 84.06%(58/69),the difference was statistically significant(P<0.05).Conclusion The combination of insulin glargine and repaglinide in the treatment of type 2 diabetes has a significant clinical effect,a low incidence of adverse reactions,a significant improvement in the clinical blood glucose level of patients,and high drug safety,which can be widely promoted and implemented.